Key Stats for Intuitive Surgical Stock
- 52-Week Range: $428 to $604
- Current Price: $458
- Street Mean Target: $577
- Street High Target: $750
- Analyst Consensus: 16 Buys / 7 Outperforms / 9 Holds / 1 Underperforms / 1 Sell
- TIKR Model Target (Dec. 2030): $777
What Happened?
Intuitive Surgical (ISRG), the dominant maker of robotic surgery systems used in minimally invasive procedures ranging from cancer removal to bariatric surgery, posted Q1 2026 revenue of $2.77 billion, a 23% increase year-over-year that beat the Street’s estimate of $2.62 billion by 6%.
The beat was driven by procedure volume: da Vinci procedures, which use the company’s flagship multi-arm surgical robots installed in hospital operating rooms worldwide, grew 16% to approximately 847,000 cases, while Ion procedures, the company’s robotic bronchoscopy platform for lung biopsy, surged 39% to approximately 43,000 cases.
The number that makes the move undeniable is EBIT: Intuitive Surgical posted $1.08 billion in operating income for Q1, a 40% jump year-over-year against the Street’s estimate of around $900 million, with EBIT margins expanding to 39% from 34% a year ago.
CEO David Rosa stated on the Q1 2026 earnings call that “Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care,” tying the performance directly to the installed base expansion strategy now covering over 11,395 da Vinci systems globally.
Procedure growth durability, the continued rollout of da Vinci 5 (which carries utilization approximately 11% higher than its predecessor) and 2026 guidance now raised to 14% to 16% da Vinci procedure growth position ISRG for an innovation-led revenue premium that management described as structurally different from prior cycles.
The European commercial footprint also just got wider: in March, Intuitive completed its acquisition of the da Vinci and Ion distribution businesses of ab medica and affiliates, adding approximately 250 employees across Italy, Spain, Portugal, and associated territories and bringing those high-growth markets under direct control.
Wall Street’s Take on ISRG Stock
The Q1 beat resolves a critical question for Intuitive Surgical stock: the margin expansion story is not a one-quarter event, it is the operational output of a maturing platform cycle, and the forward estimates now reflect that.
ISRG’s EBIT is forecast to reach around $4.5 billion in 2026, a roughly 15% increase from 2025’s $3.76 billion, with EBIT margins holding around 39% as da Vinci 5 contribution margins reached parity with the legacy Xi system this quarter and the installed base scales fixed costs faster than variable spending grows.
Thirty-three analysts cover Intuitive Surgical stock with a breakdown of 16 Buys, 7 Outperforms, 9 Holds, 1 Underperform, and 1 Sell; the mean price target sits at $577, implying approximately 26% upside from $458, and what Wall Street is waiting for is confirmation that the Japan and China headwinds which muted Asia procedure growth in Q1 do not bleed into the second half.
The target spread is genuinely wide: the Street high sits at $750 and the low at $378, with the bearish end anchored to China tender risk and the bullish end reflecting the da Vinci 5 upgrade cycle running ahead of expectations, including 232 da Vinci 5 placements out of 431 total in Q1.
Trading at roughly 44x forward earnings against a five-year historical average of approximately 55x, with EBIT growing at around 15% in 2026 and procedure volume guidance just lifted, Intuitive Surgical stock appears undervalued relative to its own valuation history at the current price, as the multiple compression has outpaced any deterioration in the underlying growth rate.
China procedure growth remaining below the corporate average, with no clarity on new charge codes or reimbursement policies expected until 2027, is the one development that, if it worsens, compresses the installed base expansion story and slows the recurring revenue flywheel.
Q2 2026 procedure volume data, specifically whether da Vinci utilization growth sustains above 4% as the installed base skews further toward da Vinci 5, is the single number to watch for confirmation that the utilization-led revenue premium has structural legs.
What Does the Valuation Model Say?
TIKR’s mid-case model projects ISRG reaching a price of around $777 by the end of 2030, assuming revenue compounding at roughly 12% annually, net income margins sustaining around 32%, and EPS growing at approximately 12% per year, a projection grounded directly in the da Vinci 5 installed base reaching scale and the Ion platform closing in on corporate-average contribution margins confirmed in Q1.
At 44x forward earnings against a decade-long average well above 50x, with EBIT expanding nearly 480 basis points year-over-year in Q1 and procedure growth guidance just lifted, Intuitive Surgical stock is undervalued at current prices relative to the earnings power the installed base now demonstrably supports.
ISRG’s investment case turns on a single question: whether the utilization and revenue-per-procedure premium from da Vinci 5 compounds fast enough to absorb the China and Japan drag before the market loses patience with the YTD underperformance.
What Has to Go Right
- Da Vinci 5’s structural utilization advantage, running roughly 11% above the legacy Xi across an installed base approaching 1,500 systems, needs to sustain as the upgrade cycle broadens, pulling recurring instrument and accessory revenue above the Street’s roughly 16% consensus growth forecast for 2026.
- Japan’s June 2026 reimbursement expansion covering 7 new robotic procedures and incremental financial support for high-volume hospital programs needs to translate into real procedure acceleration in a market that ran below the corporate average in Q1 following years of muted capital placements.
- Ion’s 39% procedure growth needs to hold, backed by the Mayo Clinic’s 2,000-patient study demonstrating 85% malignancy sensitivity and a 23-percentage-point improvement in early-stage lung cancer detection from 2019 to 2024, expanding ISRG’s TAM in a category it currently dominates without a direct competitor.
What Could Go Wrong
- China is the clearest structural risk: no clarity on new charge codes or reimbursement for robotic procedures is expected until 2027, and domestic competition already compressed Q1 China system placements to just 4 units, with no near-term policy catalyst in sight.
- Tariffs on da Vinci Xi components have already compressed full-year adjusted gross profit margin guidance by an estimated 100 basis points, memory costs and freight are flagged as additional second-half headwinds, and a 10% decline in bariatric procedures from GLP-1 drug adoption represents a structural ceiling on one of the platform’s historically highest-volume categories.
Should You Invest in Intuitive Surgical, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Intuitive Surgical stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ISRG stock on TIKR for Free →
